{"id":6641,"date":"2023-03-23T12:15:54","date_gmt":"2023-03-23T04:15:54","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=6641"},"modified":"2023-05-04T12:17:50","modified_gmt":"2023-05-04T04:17:50","slug":"eisai-to-present-new-lecanemab-data-including-research-evaluating-safety-profile-clinical-outcomes-and-quality-of-life-measures-as-well-as-other-important-alzheimers-disease-research-at-t","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2023\/03\/23\/eisai-to-present-new-lecanemab-data-including-research-evaluating-safety-profile-clinical-outcomes-and-quality-of-life-measures-as-well-as-other-important-alzheimers-disease-research-at-t\/","title":{"rendered":"EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVALUATING SAFETY PROFILE, CLINICAL OUTCOMES AND QUALITY OF LIFE MEASURES, AS WELL AS OTHER IMPORTANT ALZHEIMER\u2019S DISEASE RESEARCH, AT THE AD\/PD\u2122 2023 ANNUAL MEETING"},"content":{"rendered":"<h4 class=\"hdg-06\"><span class=\"sub\">Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai\u2019s Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer\u2019s Disease<\/span><\/h4>\n<p>&nbsp;<\/p>\n<p>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI\u2122), Eisai\u2019s anti-amyloid beta (A\u03b2) protofibril* antibody for the treatment of Alzheimer\u2019s disease (AD), at the 2023 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and related neurological disorders (AD\/PD\u2122) from March 28-April 1 in Gothenburg, Sweden and virtually. Eisai will present new findings from the company\u2019s large, global Phase III confirmatory study of lecanemab, Clarity AD, including research into the management and monitoring of amyloid-related imaging abnormalities (ARIA) and health-related quality of life (HRQoL) measures. Eisai will also host a symposium, titled \u201cPatient Clinical Care Pathway in Alzheimer\u2019s disease: Dialogue Amongst Experts,\u201d which will address the evolving landscape in AD. The lecanemab data and additional research findings from Eisai\u2019s AD portfolio will be featured in 11 presentations, including seven oral and four poster presentations.<\/p>\n<p>&nbsp;<\/p>\n<p>\u201cOur latest research examines the real-world outcomes based on lecanemab\u2019s impact on clinical results and safety, including its effect on health-related quality of life. Through our ongoing research, we hope to help simplify the patient journey and improve the lives of those living with Alzheimer\u2019s disease,\u201d said Michael Irizarry, M.D., Deputy Chief Clinical Officer and Senior Vice President of Clinical Research at Eisai Inc. \u201cIn addition to lecanemab, Eisai is presenting on several other key issues that will shape the future of Alzheimer\u2019s disease and brain health, including the next generation of clinical care and diagnostic pathways, exploration of unique populations affected by the disease, and accelerating drug development. We look forward to sharing our latest findings, including new insights from Eisai\u2019s Clarity AD trial of lecanemab, with the scientific community at AD\/PD 2023.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><b>Key Eisai Lecanemab and AD Presentations<\/b><\/p>\n<ul class=\"list-disc\">\n<li>Two presentations related to ARIA in the Clarity AD trial will be presented during an oral session on Thursday, March 30:<br \/>\n&#8211; An analysis evaluating the use of antiplatelet and anticoagulant drugs in patients who experienced ARIA.<br \/>\n&#8211; An analysis of isolated ARIA-H events in the Clarity AD trial.<\/li>\n<li>Research evaluating caregiver burden and HRQoL across multiple scales using Clarity AD data will be presented during an oral session on Thursday, March 30.<\/li>\n<li>Research studying the characterization of A\u03b2 protofibrils and the unique binding properties and mechanisms of A\u03b2 clearance of lecanemab on Friday, March 31.<\/li>\n<li>Designing The Next Generation Clinical Care and Diagnostic Pathway for Alzheimer\u2019s Disease: A presentation focused on a new pathway which interweaves clinical, biological and digital assessments to guide an individualized AD patient journey on Friday, March 31.<\/li>\n<\/ul>\n<p><b>Eisai Symposium \u2013 Patient Clinical Care Pathway in AD: Dialogue Amongst Experts<\/b><\/p>\n<p>Eisai is sponsoring a symposium featuring three prominent clinical experts in the field of AD, Dr. Alireza Atri, Dr. Sharon Cohen and Dr. Lutz Fr\u00f6lich, who will provide insights on the AD landscape, evolving diagnostic workflow, identifying appropriate patients, and addressing patient needs on Wednesday, March 29. The session aims to provide guidance on the clinical management of patients and drive effective communication between physicians and patients.<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-6638 size-full aligncenter\" src=\"https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a.png\" alt=\"\" width=\"980\" height=\"2435\" srcset=\"https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a.png 980w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-241x600.png 241w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-412x1024.png 412w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-768x1908.png 768w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-618x1536.png 618w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-824x2048.png 824w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-604x1500.png 604w, https:\/\/www.eisai.com.cn\/wordpress\/wp-content\/uploads\/2023\/05\/\u554a\u554a\u554a-284x705.png 284w\" sizes=\"(max-width: 980px) 100vw, 980px\" \/><\/p>\n<p>&nbsp;<\/p>\n<p>Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.<\/p>\n<p>* Protofibrils are large A\u03b2 aggregated soluble species of 75-5000 Kd.<sup>1<\/sup><\/p>\n<p>&nbsp;<\/p>\n<p><span class=\"txt-b\">Media Inquiries:<\/span><\/p>\n<p>Public Relations Department,<\/p>\n<p>Eisai Co., Ltd.<\/p>\n<p>+81-(0)3-3817-5120<\/p>\n<p>&nbsp;<\/p>\n<p>Eisai Europe, Ltd.<\/p>\n<p>(Europe, Australia, New Zealand and Russia)<\/p>\n<p>EMEA Communications Department<\/p>\n<p>+44 (0) 786 601 1272<\/p>\n<p><a href=\"mailto:EMEA-comms@eisai.net\">EMEA-comms@eisai.net<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>Eisai, Inc. (U.S.)<\/p>\n<p>Libby Holman<\/p>\n<p>+1-201-753-1945<\/p>\n<p><a href=\"mailto:Libby_Holman@eisai.com\">Libby_Holman@eisai.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai\u2019s Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer\u2019s Disease<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-6641","post","type-post","status-publish","format-standard","hentry","category-news-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/6641"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=6641"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/6641\/revisions"}],"predecessor-version":[{"id":6643,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/6641\/revisions\/6643"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=6641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=6641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=6641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}